These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32882898)

  • 1. Pitolisant and Other Histamine-3 Receptor Antagonists-An Update on Therapeutic Potentials and Clinical Prospects.
    Harwell V; Fasinu PS
    Medicines (Basel); 2020 Sep; 7(9):. PubMed ID: 32882898
    [No Abstract]   [Full Text] [Related]  

  • 2. Pitolisant for treating patients with narcolepsy.
    Li S; Yang J
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):79-84. PubMed ID: 31937172
    [No Abstract]   [Full Text] [Related]  

  • 3. Update on the treatment of narcolepsy: clinical efficacy of pitolisant.
    Calik MW
    Nat Sci Sleep; 2017; 9():127-133. PubMed ID: 28490912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness.
    Inocente C; Arnulf I; Bastuji H; Thibault-Stoll A; Raoux A; Reimão R; Lin JS; Franco P
    Clin Neuropharmacol; 2012; 35(2):55-60. PubMed ID: 22356925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
    Szakacs Z; Dauvilliers Y; Mikhaylov V; Poverennova I; Krylov S; Jankovic S; Sonka K; Lehert P; Lecomte I; Lecomte JM; Schwartz JC;
    Lancet Neurol; 2017 Mar; 16(3):200-207. PubMed ID: 28129985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility.
    Guevarra JT; Hiensch R; Varga AW; Rapoport DM
    Nat Sci Sleep; 2020; 12():709-719. PubMed ID: 33117007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy.
    Romigi A; Vitrani G; Lo Giudice T; Centonze D; Franco V
    Drug Des Devel Ther; 2018; 12():2665-2675. PubMed ID: 30214155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment of pediatric narcolepsy with pitolisant: A retrospective, multicenter study.
    Triller A; Pizza F; Lecendreux M; Lieberich L; Rezaei R; Pech de Laclause A; Vandi S; Plazzi G; Kallweit U
    Sleep Med; 2023 Mar; 103():62-68. PubMed ID: 36758348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pitolisant: A Review in Narcolepsy with or without Cataplexy.
    Lamb YN
    CNS Drugs; 2020 Feb; 34(2):207-218. PubMed ID: 31997137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study.
    Dauvilliers Y; Arnulf I; Szakacs Z; Leu-Semenescu S; Lecomte I; Scart-Gres C; Lecomte JM; Schwartz JC;
    Sleep; 2019 Oct; 42(11):. PubMed ID: 31529094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
    Sarfraz N; Okuampa D; Hansen H; Alvarez M; Cornett EM; Kakazu J; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(3):34222. PubMed ID: 35774905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitolisant: First Global Approval.
    Syed YY
    Drugs; 2016 Sep; 76(13):1313-1318. PubMed ID: 27438291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy.
    Setnik B; McDonnell M; Mills C; Scart-Grès C; Robert P; Dayno JM; Schwartz JC
    Sleep; 2020 Apr; 43(4):. PubMed ID: 31626696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
    Dauvilliers Y; Bassetti C; Lammers GJ; Arnulf I; Mayer G; Rodenbeck A; Lehert P; Ding CL; Lecomte JM; Schwartz JC;
    Lancet Neurol; 2013 Nov; 12(11):1068-75. PubMed ID: 24107292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review.
    Fabara SP; Ortiz JF; Anas Sohail A; Hidalgo J; Altamimi A; Tama B; Patel UK
    Cureus; 2021 Jul; 13(7):e16095. PubMed ID: 34345566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive Improvements in Children with Prader-Willi Syndrome Following Pitolisant Treatment-Patient Reports.
    Pullen LC; Picone M; Tan L; Johnston C; Stark H
    J Pediatr Pharmacol Ther; 2019; 24(2):166-171. PubMed ID: 31019411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pitolisant for the treatment of narcolepsy with or without cataplexy].
    Bruhn C
    Med Monatsschr Pharm; 2016 Aug; 39(8):324-9. PubMed ID: 29984945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use.
    Kollb-Sielecka M; Demolis P; Emmerich J; Markey G; Salmonson T; Haas M
    Sleep Med; 2017 May; 33():125-129. PubMed ID: 28449891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H
    Riddy DM; Cook AE; Shackleford DM; Pierce TL; Mocaer E; Mannoury la Cour C; Sors A; Charman WN; Summers RJ; Sexton PM; Christopoulos A; Langmead CJ
    Neuropharmacology; 2019 Jan; 144():244-255. PubMed ID: 30359639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases.
    Sadek B; Saad A; Sadeq A; Jalal F; Stark H
    Behav Brain Res; 2016 Oct; 312():415-30. PubMed ID: 27363923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.